Article

Rep. Frank Pallone Jr. on Streamlining the Anti-Cancer Drug Approval Process

Author(s):

Rep. Frank Pallone Jr.

Rep. Frank Pallone Jr., Sixth Congressional District of New Jersey, House Energy and Commerce Committee, discusses "streamlining" the FDA's drug approval process as it relates to the 21st Century Cures Act.

Rep. Frank Pallone Jr., Sixth Congressional District of New Jersey, House Energy and Commerce Committee, discusses “streamlining” the FDA’s drug approval process as it relates to the 21st Century Cures Act.

In a 344-77 vote this morning, the U.S. House of Representatives voted overwhelmingly to approve the 21st Century Cures Act.

Related Videos
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
Image of woman with blonde hair.
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
Image of woman with blonde hair.
Guiding Patients Through Shared Decision-Making in Breast Cancer Care
Image of woman with brown hair.
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer
Image of woman.
A Patient’s Journey With Colon Cancer and Her Advocacy Mission
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Colostomies and Colon Cancer, a Lifesaving Choice, Not a Last Resort
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Better Understanding Genetic Mutations Influence in Cancer Care
Related Content
Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer
March 6th 2025

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

Ryan Scott
Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.
Image of Dr. Fakih.
February 27th 2025

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

Dr. Marwan Fakih
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.
Image of doctor with brown hair.
February 25th 2025

Some KRAS Mutations Associated With Worse Outcomes in Pancreatic Cancer

Dr. Vaia Florou
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
February 21st 2025

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

Dr. Megan Menon
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.